DRAFT NICE guidance (June 2015) does not recommend ciclosporin for treating severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes. The Appraisal Committee has requested further data from the manufacturer which provides an indirect comparison of the clinical effectiveness of ciclosporin plus corticosteroids (if needed) and artificial tears, and that of corticosteroids (if needed) and artificial tears. Additionally, an economic model comparing the cost effectiveness of ciclosporin plus corticosteroids (if needed) and artificial tears, with that of corticosteroids (if needed) and artificial tears has been requested.